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Abstract 
Objectives: Clinical prediction models (CPMs) can inform decision-making concerning 
treatment initiation. Here, one requires predicted risks assuming that no treatment is given. 
This is challenging since CPMs are often derived in datasets where patients receive 
treatment; moreover, treatment can commence post-baseline - treatment drop-ins. This 
study presents a novel approach of using marginal structural models (MSMs) to adjust for 
treatment drop-in. 
Study Design and Setting: We illustrate the use of MSMs in the CPM framework through 
simulation studies, representing randomised controlled trials and observational data. The 
simulations include a binary treatment and a covariate, each recorded at two timepoints and 
having a prognostic effect on a binary outcome. The bias in predicted risk was examined in a 
model ignoring treatment, a model fitted on treatment naïve patients (at baseline), a model 
including baseline treatment, and the MSM. 
Results: In all simulation scenarios, all models except the MSM under-estimated the risk of 
outcome given absence of treatment. Consequently, CPMs that do not acknowledge 
treatment drop-in can lead to under-allocation of treatment.  
Conclusion: When developing CPMs to predict treatment-naïve risk, authors should 
consider using MSMs to adjust for treatment drop-in. MSMs also allow estimation of 
individual treatment effects. 
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1. Introduction 
Healthcare systems worldwide face escalating pressures from more people living longer with 
one or more long-term conditions. To meet this challenge, interventions must move to earlier 
stages of disease, slowing disease progression, thereby reducing the time spent in more 
expensive healthcare and increasing quality-adjusted life years. This change requires better 
targeting of limited healthcare resources. The foundation for such targeting is prediction, 
which the P4 Medicine movement frames as “predictive, preventive, personalised and 
participatory care” [1]. To this end, so-called clinical prediction models (CPMs) typically 
predict the risk of an adverse outcome (e.g. heart attack), which we hereto abbreviate as 
“risk”, based on what is currently known about an individual (e.g. covariates) [2]. One can 
use CPMs to aid clinical-decision making around treatment initiation, facilitate the discussion 
of treatment risk with the patient and underpin risk stratification analyses. 
However, with preventive interventions, the patient may not receive any appreciable relief of 
symptoms or slowing of disease; therefore, there is high variability in treatment initiation, 
adherence and duration. This uncertainty contributes to large differences between the 
treatment-effects seen in clinical trials versus real-world care. Consequently, there is a need 
for observational studies with electronic health record (EHR) data to inform clinical 
prediction. Here, we consider the development of CPMs from EHR data to guide the 
commencement of preventive interventions among patients at high risk of common, chronic 
disease events – for example, statins to help prevent heart attack or stroke. To support such 
treatment initiation decisions, the risk calculated by a CPM should apply to the patient 
assuming that no treatment is given [3]. However, CPMs are typically derived using 
observed data where patients do receive treatment, often in a time-dependent fashion. If 
such time-dependent treatments are not accounted for during CPM development, the 
subsequent risk predictions could be incorrect owing to mis-specified covariate-outcome 
associations; this has been termed the ‘treatment paradox’ [4]. 
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Recent work has, therefore, focussed on ‘subtracting’ the effect of treatment, with Groenwold 
and colleagues recommending that baseline treatment should be explicitly included in the 
modelling framework [5]. An alternative is to select a treatment naïve cohort at baseline [6]. 
Importantly, these approaches do not account for patients commencing (or changing) 
treatment after baseline, but before the outcome of interest, so-called ‘treatment drop-ins’ 
[7]. For example, QRISK3 predicts 10-year risk of cardiovascular events conditional on 
baseline risk factors. In derivation, a ‘treatment naïve’ cohort is produced by removing all 
patients who take statins at baseline [6]. This means, however, that patients who contribute 
to the 10-year risk calculation may commence statins during the 10-year follow-up, making 
the interpretation of a 10-year risk derived from such a model difficult [8]. For example, a 
patient’s predicted risk of lower than 10% may be driven by similar patients in the derivation 
cohort taking statins shortly after baseline; in this case, it would seem appropriate to 
immediately consider statins for that patient. 
The literature on accounting for treatment drop-in is sparse. One possible approach is to 
restrict analysis to a population with no treatment drop-ins, which could be achieved by 
either selecting a historical cohort before treatment was available, or selecting only patients 
who do not commence treatment during follow-up. However, the former approach is likely to 
produce a model that is not relevant to current practice [9], while the latter approach is 
clearly subject to selection bias. A refinement might be to censor patients when they 
commence treatment, but this would assume that treatment drop-ins are uninformative with 
respect to risk factor progression after baseline (i.e. treatment drop-in depends only on 
baseline risk factors) – which, again, is implausible [10]. A further possible approach is to 
estimate risk based on very large cohorts over very short time periods, thereby minimising 
the potential for treatment drop-in [7]. However, low probability short-term risks may be of 
less clinical relevance, and extrapolating these to long-term risks requires strong 
assumptions. Alternatively, Simes et al. used a penalised Cox approach for treatment drop-
in in the context of a clinical trial with differential treatment drop-in by trial arm [11]. Here, 
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one adjusts the event rates for the assumed effect of the ‘dropped in’ treatments in a time-
updated fashion. The use of external estimates of the effect of the dropped in treatments 
avoids the issue of selection bias [12], but does require an assumption of transferability of 
effect size from another population [13]. 
In this paper, we ask the question: can combining marginal structural models (MSMs) with 
predictive modelling approaches generate CPMs that better estimate risk in a variety of 
treatment regimes (current and future)? MSMs can ‘subtract’ the effect of both current and 
future treatment use, appropriately adjusting for the association between treatment drop-in 
and risk factor progression post-baseline. Importantly, MSMs can estimate the difference in 
risk for a patient who receives treatment under different regimes (i.e. the causal effect of 
treatment under the counterfactual framework). In contrast, the modelling techniques 
described above cannot be used in this way since they do not consider causal inference 
[14]. However, in practice, CPMs are often (incorrectly) used in a causal manner [15], so if 
such an interpretation were possible, this would be useful. As far as we are aware, this is the 
first use of causal modelling within the CPM framework. 
2. Methods  
2.1. MSMs within the CPM framework 
Throughout, we follow the convention that upper case letters denote random variables, while 
lower case letters denote realisations from the corresponding random variable. To formulate 
and illustrate the ideas, we consider a simplified causal model, as illustrated in Figure 1, 
considering a single treatment and two time-steps. For causal modelling we work in the 
potential outcomes framework [16]. We suppose that at time 0 we wish to estimate a 
patient’s risk of a future outcome, 𝑌, given their baseline risk factors 𝑋0. The prediction will 
be used to support the decision regarding intervention 𝐴0. We use time 1 to represent future 
values of risk factors and intervention levels, which are 𝑋1 and 𝐴1 respectively, and 
acknowledge the possible presence of unmeasured confounders 𝑈. Of course, future values 
of the risk factors, 𝑋1, are unavailable at time 0 when the prediction is being made. In 
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general, there are likely to be a large number of future times 1,2, … , 𝐾; for example, in 
computing 10-year risk of an outcome we may consider annual reviews of risk factors and 
treatments, hence 𝐾 = 9. Let ?̅? = (𝐴0, 𝐴1, … , 𝐴𝐾) denote the treatment history (or future, 
depending on one’s perspective), and let ?̅? = (𝑋0, 𝑋1, … , 𝑋𝐾). Let ?̅?−0 = (𝑋1, … , 𝑋𝐾), let ?̅? =
0̅  mean no treatment received at any time, and write ?̅?𝑘−1 to mean the treatment history up-
to time 𝑘 − 1. We could also consider multiple treatments, where each 𝐴𝑘 is a vector of 
length 𝑚 to represent 𝑚 treatments. One could regard this as a partially observable Markov 
decision process [17]. 
 
 
A CPM seeks, at time 0, to determine future risk of 𝑌 = 1, using the information currently 
available (i.e. 𝑋0, and potentially 𝐴0). There are various ways we could consider handling 
treatment, which correspond to different causal estimands. We use the notation that 𝑍(𝐵 =
𝑏) refers to the value of 𝑍 given that we intervene to set 𝐵 to value 𝑏. 
E1. 𝐸[𝑌|𝑋0] – the risk of 𝑌, disregarding the intervention. 
E2. 𝐸[𝑌(𝐴0 = 0)|𝑋0] – the risk of 𝑌 given that we do not intervene now, and may or may 
not intervene in the future. 
Figure 1: Causal diagram for simplified example. 
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E3. 𝐸[𝑌(?̅? = 0̅)|𝑋0] – the risk of 𝑌 given that we do not intervene now, nor do we 
intervene in the future. 
E4. 𝐸[𝑌(𝐴0 = 1)|𝑋0] – the risk of 𝑌 given that we intervene now, and may or may not 
intervene in the future. 
E5. 𝐸[𝑌(?̅? = 1̅)|𝑋0] – the risk of 𝑌 given that we intervene now, and continue to intervene 
in the future. 
Most existing prognostic models provide estimates like E1 or E2. Note that, in the absence 
of unmeasured confounding, 𝑈, the observed risk 𝐸[𝑌|𝑋0, 𝐴0 = 0] is a valid estimator for E2. 
However, calculating the risk based on not intervening immediately may provide 
inappropriate reassurance, since, as already discussed, a low risk may be driven by data 
from patients who commence the intervention shortly after time 0. 
Therefore, E3 is the treatment-naïve risk that is truly of interest to support the decision of 
whether to intervene. However, even in the absence of unmeasured confounding, E3 is 
challenging to estimate, since standard regression estimators are not valid whether or not 
we condition on ?̅?−0 [18]. In the risk prediction setting, it is easy to intuitively see this. If we 
do not condition, the estimate 𝐸[𝑌|𝑋0, ?̅? = 0̅] is prone to a ‘healthy survivor’ bias since 
patients in the development cohort who remain untreated throughout are likely to have future 
risk factors that are better than similar patients who initiate treatment at some point. 
Conversely, if we do condition, an estimate of the form 𝐸[𝑌|?̅? , ?̅? = 0̅] will mask some of the 
benefits of the intervention since these manifest in ?̅?−0, not to mention that the model would 
be useless in practice since ?̅?−0 is unknown at time 0. 
The solution to estimating risks of the form E3 is the MSM [18,19], which applies a 
reweighting to the population to ‘break’ the arrows from ?̅? to ?̅?, and provides a valid 
estimator for E3 in the absence of unmeasured confounding. In the usual application of 
MSMs for causal inference, we would consider conditioning only on variables that moderate 
the treatment effect. In the CPM case, however, we condition on variables that have a 
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prognostic effect only (i.e. those that do not modify the effect of treatment). Hence, we would 
like to fit a model within strata of 𝑋0.  
The proposed approach then proceeds as follows. 
1. Calculate stabilized weights for each individual 𝑖, using the formula: 
𝑠𝑤𝑖 = ∏(?̂?𝑘𝑖
∗ )𝑎𝑘𝑖(1 − ?̂?𝑘𝑖
∗ )1−𝑎𝑘𝑖  / {∏(?̂?𝑘𝑖 )
𝑎𝑘𝑖(1 − ?̂?𝑘𝑖)
1−𝑎𝑘𝑖
𝐾
𝑘=0
} .
𝐾
𝑘=0
 
Here, ?̂?𝑘𝑖
∗  is the estimated predicted value from a model for logit 𝑃[𝐴𝑘 = 1|?̅?𝑘−1, 𝑋0],  
while ?̂?𝑘𝑖 is the estimated predicted value from a model for logit 𝑃[𝐴𝑘 = 1|?̅?𝑘−1, ?̅?𝑘−1]. 
We note here that this follows the classic development of calculating weights for a 
marginal structural model [18], besides that, to reiterate, 𝑋0 comprises all baseline 
variables that are prognostic for 𝑌, rather than only the effect modifiers.  
2. Using the derived stabilized weights, fit the model 
𝑙𝑜𝑔𝑖𝑡 𝑃[𝑌 = 1|𝑋0, ?̅?] =  𝛽0 + 𝛽𝑋𝑋0 + ∑(𝛽𝐴𝑘𝐴𝑘 + 𝛽𝐴𝑘𝑋𝐴𝑘𝑋0)
𝐾
𝑘=0
 
The model allows any of the variables in 𝑋0 to modify the effect of treatment. We may 
fix by design some (or all) of the elements of 𝛽𝐴𝑘𝑉 to 0. Similarly, a subset of 𝑋0 may 
be considered by fixing some of 𝛽𝑋 to 0. 
Succinctly the strategy is to adjust for variables that are available at baseline and are to be 
used as predictors, plus treatment strategy at baseline and in the future, then to reweight for 
all remaining variables that might be on the treatment causal pathways. This strategy, under 
the assumption of no unmeasured confounding, yields valid estimates for causal effects of 
the form E3. Generating a CPM in this manner allows us not only to estimate treatment-
naïve risk that accounts for treatment drop-in, but also to estimate the (counterfactual) 
causal effect of treatment for a patient with given baseline risk factors. 
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2.2. Simulation Design: overview 
We designed a simulation study to demonstrate the properties of the proposed method, 
compared with current approaches of handling treatment when developing CPMs. 
Specifically, the aim of the simulation study was to investigate the extent of bias in predicted 
risk by failing to account for treatment drop-ins. For simplicity of illustration, we again 
consider a scenario where we have one treatment option and two timepoints – time 0 when 
the predictions are to be made, a ‘future’ time 1. At each timepoint, we record information on 
a single time varying continuous covariate and a binary treatment indicator (also time 
varying) (Figure 2). While in practice CPMs include more than one risk factor, one can 
imagine that the single covariate is a summary of multiple risk factors; this follows similar 
reasoning to previous simulation studies [5]. Both the covariate and the treatment indicator 
have a prognostic effect at each timepoint on a binary outcome, in the sense that treatment 
reduces risk of outcome while higher values of the covariate increase risk. For example, one 
could imagine that 𝑌 represents a cardiovascular event, ?̅? is cholesterol (HDL ratio), and ?̅? 
statins. 
 
Several simulation scenarios were considered, representing a mixture of randomised 
controlled trials (where treatment allocation at baseline is independent of the continuous 
Figure 2: Causal diagram and parameters of the data-generating mechanism. 
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covariate) and observational studies (where treatment allocation at each timepoint is 
conditional on the continuous covariate) under different causal pathways (see below and 
Table 1 for details). Within the generated data, we fit a model simply ignoring treatment, a 
treatment naïve model (fitted on all patients without treatment at baseline), a model 
incorporating baseline treatment as a predictor, and the MSM. 
The predictive performance of each modelling technique was then calculated in two ‘test’ 
datasets that were independent of the data used to derive each model (details below). For 
each simulation scenario, the relationship between 𝐴0 and 𝑋1 was controlled through the 
value of 𝛾, which was varied through (-3, -2.5, -2, -1.5, -1, -0.5, 0). Since we assumed that 
treatment was effective and the covariate increased risk of outcome, we did not consider 
positive values of 𝛾. In the context of our example, 𝛾 represents the cholesterol-lowering 
effect of statins. For each value of 𝛾, we repeated the simulation across 1000 iterations. The 
predicted performance was averaged across iterations and empirical standard errors were 
calculated. The simulation was implemented in R version 3.4.0 [20], and the code is 
available as an online data supplement. 
2.3. Simulation Design: data-generating mechanism 
Within each iteration of a given simulation scenario, data of 𝑁 = 10,000 observations were 
generated, acting as ‘development’ data, on which one is interested in deriving a CPM. The 
steps of the data-generating mechanism were: 
1. Simulate 𝑁 realisations of 𝑋0 ∼ N(0,1) 
2. Simulate 𝑁 realisations of 𝐴0 ∼ Binomial(πi,A0) where 
πi,A0 =
exp (𝛼0 + 𝜙𝑥0𝑖)
1 + exp (𝛼0 + 𝜙𝑥0𝑖)
 
3. Simulate 𝑁 realisations of 𝑋1 ∼ N(𝑋0 + 𝛾𝐴0, 1) 
4. Simulate 𝑁 realisations of 𝐴1 ∼ Binomial(πi,A1) where 
πi,A1 = {
exp (𝛼1 + 𝜙𝑥1𝑖 + 𝜃𝑎0𝑖)
1 + exp (𝛼1 + 𝜙𝑥1𝑖 + 𝜃𝑎0𝑖)
if simulating an observational study
𝜃𝑎0𝑖 for 𝜃 ∈ [0,1] if simulating a RCT
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5. Simulate 𝑁 realisations of 𝑌 ∼ Binomial(πi,y) where 
log (
πi,y
1 − πi,y
) = 𝛼𝑌 + 𝛽𝑋0𝑥0𝑖 + 𝛽𝑋1𝑥1𝑖 + 𝛽𝐴0𝑎0𝑖 + 𝛽𝐴1𝑎1𝑖 
The values of the above parameters across simulation scenarios are given in Table 1, each 
representing different modelling situations. Across all simulation scenarios, we assumed that 
the covariate increased the risk of outcome (i.e. 𝛽𝑋0 = 𝛽𝑋1 = log (1.5)), the treatment 
decreased risk of outcome (𝛽𝐴0 = 𝛽𝐴1 = log (0.5)), and the mean event rate for the outcome, 
𝑌, was set at 20%. The first scenario (denoted “RCT: 10% dropout”) aims to mimic 
development of a CPM within a randomised controlled trial, in which treatment was randomly 
allocated to 50% of observations at baseline and independent of their baseline covariate 
(𝜙 = 0). Here, we assumed that 10% of those treated at baseline were untreated at 
timepoint one (i.e. 90% remained treated throughout, with 𝜃 = 0.9), and that untreated 
patients at baseline remained untreated at timepoint one. We conducted sensitivity analyses 
across a range of RCT 𝜃 values, with the results being quantitatively similar to those 
presented for 𝜃 = 0.9, and so are omitted for clarity (available on request). In contrast, the 
remaining two scenarios were based on observational data, in which one unit increase in 𝑋0 
or 𝑋1 doubled the odds of been given treatment at the corresponding time, 𝜙 = log (2), and 
those on treatment at baseline (time zero) had twice the odds of being on treatment at time 
one (i.e. 𝜃 = log (2)). Scenario 2 (denoted “Observational: 50% treated”) assumed that 50% 
of patients were on treatment at each timepoint, while scenario 3 (denoted “Observational: 
20% treated”) lowered this to 20% of patients at each timepoint. 
2.4. Simulation Design: modelling methods and performance measures 
The following models were fit within the development set: a model ignoring treatment, a 
model developed on a treatment naïve cohort, a model including baseline treatment, and the 
MSM. The model ignoring treatment modelled the log odds of 𝑌 with the baseline risk factor, 
𝑋0 as the only covariate (i.e. logit(E[𝑌 |𝑋0]) = 𝛽0
′ + 𝛽
𝑋0
′ 𝑥0𝑖); the treatment naïve model was 
similar, except that only observations with no treatment at baseline (i.e. those 𝑖 such that 
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𝑎0𝑖 = 0) were used in model fitting. The model including baseline treatment was fit as 
logit(E[𝑌 |𝑋0, 𝐴0]) = 𝛽0
′ + 𝛽𝑋0
′ 𝑥0𝑖 + 𝛽𝐴0
′ 𝑎0𝑖. Finally, the MSM modelled the full treatment 
pathway and the baseline covariate as logit(E[𝑌 |𝑋0, ?̅?]) = 𝛽0
′ + 𝛽𝑋0
′ 𝑥0𝑖 + 𝛽𝐴0
′ 𝑎0𝑖 + 𝛽𝐴1
′ 𝑎1𝑖, 
under the weighted log-likelihood 
𝑙(𝜷) = ∑ 𝑠𝑤𝑖𝑦𝑖 log(𝜋𝑖,𝑌) + 𝑠𝑤𝑖(1 − 𝑦𝑖)log (1 − 𝜋𝑖,𝑌)
𝑁
𝑖=1
 
where 𝑠𝑤𝑖 were calculated as described above. Here, 
logit(?̂?𝑘𝑖) = logit(𝑃(𝐴𝑘 = 1|?̅?𝑘−1, ?̅?𝑘)) = 𝜔0 + 𝜔1𝑎(𝑘−1)𝑖 + ∑ 𝜔𝑗+2𝑥(𝑗)𝑖
𝑘
𝑗=0
 
logit(?̂?𝑘𝑖
∗ ) = logit(𝑃(𝐴𝑘 = 1|?̅?𝑘−1, 𝑋0)) = 𝜔0
∗ + 𝜔1
∗𝑎(𝑘−1)𝑖 + 𝜔2
∗𝑥0𝑖 , 
with 𝑎(−1)𝑖 = 0. Thus, the numerator probabilities of the stabilized weights were modelled 
through a logit-linear combination of the treatment indication at the previous timepoint and 
the baseline covariate. The denominator probabilities were modelled as a logit-linear 
combination of the previous timepoint treatment and all previous covariate information. 
We generated two further independent test datasets, each of size 𝑁 = 100,000 observations, 
which were used to assess performance of each modelling method. Test dataset 1 was 
generated under the same data-generating mechanism described above for the 
development dataset. Test dataset 2 set 𝐴0 = 𝐴1 = 0 for all patients, but otherwise used the 
same data-generating mechanism (Table 2), which corresponds to a policy intervention in 
which treatment is withheld from all patients at all times. Predictive performance was 
assessed in terms of calibration, discrimination and Brier score (mean squared difference 
between observed and expected outcome) [21]. Calibration is the agreement between the 
observed event rate and that expected from the model, while discrimination is the ability of 
the model to distinguish cases and controls. Calibration was assessed via the calibration 
intercept and slope, estimated from a logistic regression model for the outcome with the 
linear predictor from a model as the only covariate [22]. A perfectly calibrated model will 
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have calibration intercept and slope of zero and one, respectively. Discrimination was 
assessed through the area under the receiver operating characteristic curve (AUC). 
Across the two test datasets, three performance-settings were considered (Table 2). The 
first, (denoted “performance-setting: Mix of Treatment (MT)”) used test dataset 1 to estimate 
performance, thus representing performance on (treated and untreated) samples drawn from 
a similar population to the development set; this was used to examine estimate E1. The 
second performance-setting (denoted “performance-setting: No Baseline Treatment (NBT)”) 
estimated performance in test dataset 1, but restricted to those observations who did not 
receive treatment at baseline (i.e. for all 𝑖 such that 𝑎0𝑖 = 0), giving an indication of estimate 
E2. Finally, “performance-setting: No Treatment Throughout (NTT)” used test dataset 2, to 
examine the bias in the calculation of the causal effect E3 for each modelling method. 
Moreover, in practice, individuals might initiate treatment if the predicted (E3) risk exceeded 
an a priori chosen treatment threshold. Thus, to examine the impact of each modelling 
strategy on treatment decision-making, we calculated the proportion of patients within test 
dataset 2 where the predicted risk from a given modelling strategy was larger than a range 
of treatment thresholds from 5% to 70%.  
3. Results 
3.1. Calibration  
Within the randomised controlled trial setting (RCT: 10% dropout simulation scenario), the 
model including baseline treatment and the MSM were well calibrated across all three 
performance-settings (Figure 3). In contrast, the model ignoring treatment underestimated 
E2 (performance-setting: NBT) and E3 (performance-setting: NTT), while the treatment-
naïve model over-predicted E1 (performance-setting: MT). In both observational simulation 
scenarios (Observational: 20% treated and Observational: 50% treated), all models except 
the MSM provide biased estimates of E3 (performance-setting: NTT), with calibration 
intercepts significantly larger than zero (Figure 3); here, the under-estimation was most 
pronounced for the model that ignored treatment. Since the MSM can include the full 
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treatment pathway, this model had a calibration intercept close to zero across all values of 𝛾. 
Figure 3 shows better calibration of estimate E3 for the modelling methods that ignore 
treatment drop-ins when the proportion of treated observations at each timepoint decreased 
(Observational: 50% treated simulation scenario vs. Observational: 20% treated simulation 
scenario).  
 
The RCT: 10% dropout simulation scenario demonstrated calibration slopes not significantly 
different from one across all models except the model ignoring treatment in performance-
Figure 3: Calibration intercept in each simulation scenario (rows), across all 
performance-settings (columns) and values of 𝛾. In Performance-settings NBT and NTT, 
the calibration intercept for the treatment-naïve model and the model treatment are 
indistinguishable. 
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setting: NBT and performance-setting: NTT (Figure 4). In contrast, the calibration slope for 
the model ignoring treatment, the treatment naïve model and the model including baseline 
treatment was significantly above one in Observational: 50% treated and Observational: 
20% treated simulation scenarios. This indicated that, in these observational circumstances, 
the coefficient of 𝑋0 in all models apart from the MSM was too low. 
3.2. Discrimination and Brier score 
The discrimination of all models for simulation scenario RCT: 10% dropout were identical 
across performance-settings: NBT and NTT (Supplementary Figure 1). Since 𝑎0𝑖 = 0 for all 
Figure 4: Calibration slope in each simulation scenario (rows), across all performance-settings 
(columns) and values of 𝛾. In Performance-settings NBT and NTT, the calibration slope for the 
treatment-naïve model and the model treatment are indistinguishable. 
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𝑖 in performance-settings NBT and NTT, all models are ‘ranking’ patients based on the same 
continuous covariate 𝑋0 (although the corresponding estimate will be slightly different across 
all modelling methods); thus, the identical discrimination in these settings is expected. For 
performance-setting MT, the MSM resulted in the highest discrimination and lowest Brier 
score across all values of 𝛾, with all models converging when 𝛾 = 0 (Supplementary Figure 
1). This is likely the effect of the MSM model being able to incorporate the full treatment 
pathway (i.e. adjusts for both 𝐴0 and 𝐴1). The AUC and Brier score were quantitatively 
similar in both observational simulation scenarios to those in the RCT scenario, and so are 
omitted for clarity. 
 
3.3. Treatment decision-making 
We examined the proportion of patients who would have treatment initiated at baseline if 
E[𝑌 = 1 |𝑋0, ?̅? = 0] exceeded a given treatment threshold; Figure 5 depicts the results 
obtained from the Observational: 50% treated simulation scenario. Given that only the MSM 
provides valid estimates of E3, we take this to be the reference and find that the model 
ignoring treatment, the treatment-naïve model and the model including baseline treatment all 
under-allocated treatment. For example, when 𝛾 = 0 and taking a 40% treatment threshold, 
the proportion of patients allocated to treatment was 2.9%, 14.9%, 15.1% and 29.2% for the 
model ignoring treatment, the treatment-naïve model, the model including baseline treatment 
and the MSM, respectively (Figure 5). Similar results were obtained across the other 
simulation scenarios (Supplementary Figure 2 and 3). 
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4. Discussion 
This paper introduces the idea of embedding CPMs within a counterfactual causal 
framework, using marginal structural models to adjust for treatment drop-in, thereby better 
reflecting real-world healthcare. This allows for estimation of treatment-naïve risk that 
appropriately adjusts for treatment drop-in. Moreover, we can estimate causal effects of 
treatment within strata of baseline risk. 
Our study shows that the common practice of simply ignoring time-dependent treatment in 
CPM development provides biased outcome risk estimates in untreated individuals. Although 
including baseline treatment within the model provided some protection from this, only the 
Figure 5: Proportion of patients in the Observational 50% treated simulation scenario who 
would initiate treatment at baseline if their predicted risk given no current or future intervention 
exceeded a given treatment threshold. Note, 𝛾 values of -2.5, -1.5 and -0.5 have been removed 
for clarity. The treatment-naïve model and the model including baseline treatment are identical. 
18 
 
MSM resulted in valid risk estimates, given no current or future intervention. Since CPMs are 
often used in the context of stop-go clinical decision-making regarding treatment, these 
results demonstrate that current approaches to developing CPMs are ill-suited to common 
uses and provide misspecified covariate-outcome associations in the presence of (time-
dependent) treatment. Failing to account for treatment drop-ins led to significant under-
prediction in risk E3 and a corresponding under-allocation to treatment. While the literature 
on handling treatments in CPM development is sparse, the results from this paper support 
those of previous studies [5,7].  As reported previously, within a simple two-armed 
randomised controlled trial (with no treatment drop-ins), all of the modelling strategies except 
ignoring treatment provided valid estimates of E3 [5]. Nevertheless, one needs to use 
observational datasets to capture the high variability in treatment initiation, adherence and 
duration that occur in practice. In such situations, while explicitly modelling baseline 
treatment is preferred to modelling within a treatment-naïve cohort [5], the current study 
suggests that CPMs need to be framed within a counterfactual causal framework to truly 
support using them in treatment initiation settings. To the best of our knowledge, this is the 
first study to propose such a causal framework for developing a CPM. 
Post development, CPMs need to be validated in samples similar to (internal validation) and 
distinct from (external validation) the development cohort [23]. Performance-setting MT in 
the current simulation study aimed to represent an internal validation of models within a 
cohort driven by the same underlying processes and with the same ratio of treated to non-
treated observations. In such a situation, the treatment-naïve modelling method was 
miscalibrated, which is unsurprising given that performance-setting MT tests this model in 
both treated and non-treated observations. However, poor performance can be expected if 
models ignoring treatment or only modelling baseline treatment are then applied/validated in 
treatment-naïve populations (performance-setting: NTT). Importantly, all published CPM 
validation studies, whether internal or external, focus on the model’s ability to estimate E2. If 
aiming to guide treatment initiation, one needs to assess the ability to estimate E3. Here, the 
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MSM was well calibrated in all circumstances we considered since it can include the full 
treatment pathway. Based on such findings, we recommend that MSMs be used to develop 
clinical prediction models where treatment drop-ins are expected. 
We acknowledge some limitations, which require further work to overcome. First, as with all 
methods that use causal inference for observational data, we assume no unmeasured 
confounding. Particularly in the case of using routinely collected observational data for 
causal inference, unmeasured confounding is a significant threat, and sensitivity analysis 
should be conducted [24]. Second, the usual requirements for building a CPM needs more 
careful consideration. For example, the implications of introducing a causal structure on 
model performance and validity. Third, we note that using a CPM is itself an intervention, 
suggesting that a meta-model with rapid feedback may be required to understand how the 
use of the CPM may be changing patient care [25]. Finally, we have only considered a single 
treatment and single future point in time. In principle, the extension to multiple treatments 
and times sits within the methodology, although model complexity may become an issue. 
More serious is that, in routinely collected observational data, risk factors may be observed 
at different times, and are likely to be subject to informative observation [26] (e.g. patients 
being measured more often when they are sicker [27]). Methods are needed to overcome 
such challenges within this framework. Moreover, we recommend that future work consider 
scenarios with time-dependent drop-in/out. For example, the mean duration of adherence to 
preventive therapy with statins is 18 months, but this might vary with disease stage, 
symptoms and perceived risk of adverse outcomes. Therefore, a paradoxical increase in risk 
may arise from hastening intervention without considering dropout. 
In conclusion, we have shown that marginal structural models can improve treatment-naïve 
risk estimation through better adjustment for treatment-drop-ins, avoiding a potentially 
serious underestimate of treatment-naïve risk. More generally, the quest for P4 Medicine can 
be advanced by improving CPMs with a counterfactual causal framework that properly 
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reflects real-world healthcare, as recorded in the abundant digital records available for model 
development. 
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Tables 
Table 1: Description and parameter formulisation across each simulation scenario. 
Simulation Scenario Description Parameter values 
RCT: 10% dropout* A randomised controlled trial 
with treatment randomly 
allocated to 50% of the 
population at baseline, with 
10% treatment dropout. 
𝜙 = 0 
𝛼0 𝑠. 𝑡. 𝑃(𝐴0 = 1) = 0.5 
πi,A1 = 𝜃𝑎0𝑖 
𝜃 = 0.9 
𝛼𝑌 s.t. 𝑃(𝑌 = 1) = 0.2 
𝛽𝐴0 = 𝛽𝐴1 = log (0.5) 
𝛽𝑋0 = 𝛽𝑋1 = log (1.5) 
Observational: 50% 
treated 
An observational study 
where 50% of the population 
have treatment. 
𝜙 = log (2) 
𝜃 = log (2) 
𝛼𝑗: 𝑗 = 0,1 s.t. 𝑃(𝐴𝑗 = 1) = 0.5 
𝛼𝑌 s.t. 𝑃(𝑌 = 1) = 0.2 
𝛽𝐴0 = 𝛽𝐴1 = log (0.5) 
𝛽𝑋0 = 𝛽𝑋1 = log (1.5) 
Observational: 20% 
treated 
An observational study 
where 20% of the population 
have treatment. 
𝜙 = log (2) 
𝜃 = log (2) 
𝛼𝑗: 𝑗 = 0,1 s.t. 𝑃(𝐴𝑗 = 1) = 0.2 
𝛼𝑌 s.t. 𝑃(𝑌 = 1) = 0.2 
𝛽𝐴0 = 𝛽𝐴1 = log (0.5) 
𝛽𝑋0 = 𝛽𝑋1 = log (1.5) 
*: results from across a range of percentage dropouts (values of 𝜃) gave similar results as 
those for the RCT: 10% dropout scenario and so are omitted. They are available on request. 
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Table 2: Description of the performance-settings and corresponding test datasets. 
Performance-setting Description Test set data-generating 
mechanism 
Mix of Treatment (MT) Model validation on samples 
drawn from a similar 
population to the 
development set. 
Corresponds to estimating 
E1. 
Test set 1 (𝑁 = 100,000):  
Generated under exactly the 
same process as the 
development cohort. 
No Baseline 
Treatment (NBT) 
Model validation on samples 
drawn from a similar 
population to the 
development set, but 
restricted to those without 
treatment at baseline. 
Corresponds to estimating 
E2. 
Test set 1 (𝑁 = 𝑃(𝐴0 = 0) ×
100,000):  
Generated under exactly the 
same process as the 
development cohort, but restricted 
to examining {𝑖 ∈ [1, 𝑁]: 𝑎0𝑖 = 0}. 
No Treatment 
Throughout (NTT) 
Model validation in a 
population where treatment 
is withheld from all patients, 
but where the distribution of 
covariates is similar to the 
development cohort. 
Corresponds to estimating 
E3. 
Test set 2 (𝑁 = 100,000): 
generated as 
𝑋0 ∼ N(0,1) 
𝑋1 ∼ 𝑁(𝑋0, 1) 
𝐴0 = 𝐴1 = 0 
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Supplementary Material 
 
Using marginal structural models to adjust for treatment drop-in when developing 
clinical prediction models 
 
Supplementary Figures 
 
Supplementary Figure 1: AUC (top row) and Brier score (bottom row) across all 
performance-settings and values of 𝛾 for the RCT: 10% drop-out simulation scenario. 
Quantitatively similar results were observed across all other simulation scenarios. 
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Supplementary Figure 2: Proportion of patients in the RCT: 10% drop-out simulation 
scenario who would initiate treatment at baseline if their predicted risk given no current or 
future intervention exceeded a given treatment threshold across each model. Note, 𝛾 values 
of -2.5, -1.5 and -0.5 have been removed for clarity. The treatment-naïve model, the model 
including baseline and the MSM model are identical. 
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Supplementary Figure 3: Proportion of patients in the Observational 50% treated 
simulation scenario who would initiate treatment at baseline if their predicted risk given no 
current or future intervention exceeded a given treatment threshold across each model. 
Note, 𝛾 values of -2.5, -1.5 and -0.5 have been removed for clarity. The treatment-naïve 
model and the model including baseline are identical. 
 
 
